Renal Ultrasonography Predicts Worsening Renal Function in Patients with Heart Failure Under Tolvaptan Administration
ESC Heart Failure · 2024
DOI: 10.1002/ehf2.14740 ↗Kurz gefasst
Fachartikel in der Zeitschrift ESC Heart Failure, 2024. Verfasst von Nobukiyo Tanaka und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Ichinomiya Nishi Hospital, 1 Kaimei-hira, Ichinomiya, 494-0001, Japan. Hauptthemen laut MEDLINE: Antidiuretic Hormone Receptor Antagonists, Glomerular Filtration Rate, Heart Failure, Kidney. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Aims
Renal dysfunction in patients with chronic heart failure predicts a poor prognosis. Tolvaptan has a diuretic effect in patients with chronic kidney disease and heart failure without adverse effects on renal function. We aimed to determine the effects of tolvaptan and predictors of worsening renal function in patients with heart failure. Methods and results This post hoc analysis was a sub-analysis of a single-centre prospectively randomized trial on the early and short-term tolvaptan administration. We enrolled 201 participants with decompensated heart failure between January 2014 and March 2019 (early group, n = 104; age: 79.0 ± 12.8 years; late group, n = 97; age: 80.3 ± 10.8 years). Renal ultrasonography was performed before and after the administration of tolvaptan. Urine output and oral water intake significantly increased during tolvaptan administration. The difference between water intake and urine volume increased during tolvaptan administration. Changes in body weight, blood pressure, heart rate, and estimated glomerular filtration rate (eGFR) in both groups were comparable. The changes in peak-systolic velocity (PSV), acceleration time (AT) of the renal arteries, and resistance index were comparable. The changes in PSV and end-diastolic velocity (EDV) of the interlobar arteries increased following tolvaptan administration (Δmax PSV: 0.0 ± 14.8 cm/s before tolvaptan vs. 5.6 ± 15.7 cm/s after tolvaptan, P = 0.002; Δmean PSV: 0.4 ± 12.3 vs. 4.9 ± 12.7 cm/s, P = 0.002; Δmax EDV: −0.2 ± 3.5 vs. 1.4 ± 4.0 cm/s, P = 0.001; Δmean EDV: −0.0 ± 3.1 vs. 1.1 ± 3.4 cm/s, P = 0.003). The renal artery AT was negatively correlated with the eGFR (Δmax AT: beta = −0.2354, P = 0.044; Δmean AT: beta = −0.2477, P = 0.035).
Conclusions
Tolvaptan increased the PSV and EDV of the interlobar artery, which may mean tolvaptan increased renal blood flow. The renal artery AT may be a surrogate for worsening renal function.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular Medicine, Ichinomiya Nishi Hospital, 1 Kaimei-hira, Ichinomiya, 494-0001, Japan.
ORCID-Profile: Nobukiyo Tanaka
Zitieren
APA
Tanaka, N., Furukawa, Y., Maeda, T., Ishihara, H., Dan, K., Teramura, M., Ichihashi, K., Takase, T., Takahashi, Y., Tsuzura, D., Shinoda, A., Fujii, M., Okada, H., Itabashi, F., & Teramoto, T. (2024). Renal Ultrasonography Predicts Worsening Renal Function in Patients with Heart Failure Under Tolvaptan Administration. ESC Heart Failure. https://doi.org/10.1002/ehf2.14740
Vancouver
Tanaka N, Furukawa Y, Maeda T, Ishihara H, Dan K, Teramura M, et al. Renal Ultrasonography Predicts Worsening Renal Function in Patients with Heart Failure Under Tolvaptan Administration. ESC Heart Failure. 2024. doi:10.1002/ehf2.14740
BibTeX
@article{Tanaka2024,
author = {Tanaka, Nobukiyo and Furukawa, Yoshio and Maeda, Takuya and Ishihara, Hiroki and Dan, Kazuhiro and Teramura, Masanori and Ichihashi, Kei and Takase, Tetsuro and Takahashi, Yuya and Tsuzura, Daichi and Shinoda, Akira and Fujii, Masato and Okada, Hisashi and Itabashi, Fumiharu and Teramoto, Tomohiko},
title = {Renal Ultrasonography Predicts Worsening Renal Function in Patients with Heart Failure Under Tolvaptan Administration},
journal = {ESC Heart Failure},
year = {2024},
doi = {10.1002/ehf2.14740}
}
EUVIMED